Rocket Pharmaceuticals (RCKT) Shares Outstanding (Weighted Average) (2014 - 2026)

Rocket Pharmaceuticals has disclosed Shares Outstanding (Weighted Average) across 13 years of filings, most recently posting $112.1 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $112.1 million, up 1.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $112.1 million (up 1.85% YoY), and the FY2025 annual result was $111.1 million, up 17.21% from the prior year.
• Shares Outstanding (Weighted Average) came in at $112.1 million for Q1 2026 at Rocket Pharmaceuticals, up from $111.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $112.1 million in Q1 2026 to a low of $64.5 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $93.5 million (2024), against an average of $89.4 million.
• Across the five-year window, Shares Outstanding (Weighted Average) advanced 23.63% in 2023 and advanced 1.85% in 2026, its largest moves.
• Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $68.1 million in 2022, then climbed by 23.27% to $84.0 million in 2023, then advanced by 12.85% to $94.8 million in 2024, then rose by 17.21% to $111.1 million in 2025, then gained by 0.91% to $112.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $112.1 million (Q1 2026), $111.1 million (Q4 2025), and $111.6 million (Q3 2025), per Business Quant data.